石药集团(01093)尾盘涨超10%，暂领涨蓝筹。截至发稿，涨10.07%，报6.12港元，成交额10.82亿港元。

消息面上，石药集团此前发布公告，集团开发的SYS 6041(抗体偶联药物)的试验性新药(IND)申请已获得美国FDA批准，可以在美国开展临床研究。该产品已于2025年1月获得中华人民共和国国家药品监督管理局批准在中国开展临床试验。

此外，石药集团公告，集团开发的磷酸奥司他韦干混悬剂(0.36g)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件，并视同通过仿制药质量和疗效一致性评价。该产品的获批将进一步丰富本集团在抗感染治疗领域的产品线。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.